Get started
Mereo BioPharma Group plcMereo BioPharma Group plcMereo BioPharma Group plc

Mereo BioPharma Group plc

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

MREO trade ideas

MREO - Huge Cup and HandleMereo BioPharma Group PLC is a multi-asset, clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its oncology product candidate is etigilimab, for patients with solid tumors. Some of the other products in the pipeline are setrusumab, alvelestat, leflutrozole, navicixizumab, and acumapimod. Disclaimer: This is not financial advice. MREO Stock Outlook: A Deep Dive into Potential Growth MREO stock stands out with its promising setup, driven by significant upcoming catalysts and technical patterns. Here’s a refined analysis for a clearer understanding: Key Catalysts on the Horizon: With two major catalysts expected by the end of 2024, MREO presents a compelling case for potential investors. These catalysts could significantly impact the stock's valuation and market perception. Technical Pattern Observation: A 'Cup and Handle' formation is currently being observed, indicating a potential for bullish continuation. This pattern is often seen as a precursor to upward price movements if completed successfully. Analyst Sentiment: The bullish stance from analysts on MREO adds a layer of confidence, suggesting that the stock has solid fundamentals or upcoming events that could drive its price higher. Market Sentiment Consideration : The overall bullish sentiment in the market is a crucial factor for this stock's success. A market correction could adversely affect the play, highlighting the need for timely market evaluation. Entry Point Analysis: A potential pullback to the $3.0 zone is identified as an attractive entry point, offering a favorable risk-reward ratio for entering the trade. Risk Management Strategies: Stop Loss (SL) Placement: Setting a stop loss at $2.3 helps protect the investment from unexpected downturns, a crucial step in managing potential risks. Take Profit (TP) Levels: Establishing take profit levels at approximately $4.0 and $6.5 allows investors to lock in gains while aiming for substantial upside potential. Chart Insights: The detailed chart analysis provides essential insights into the stock's technical setup, including support and resistance levels, the cup and handle pattern, and potential indicators for entry and exit points. This visual aid is invaluable for making informed decisions. Investment Approach: Considering the speculative nature of this stock, coupled with its reliance on broader market sentiment and specific catalysts, a careful and measured approach to trading is recommended. Investors should stay informed on market trends and adjust their strategies as needed to navigate potential volatility.
NASDAQ:MREOLong
by meitshels_smell_trades
$MREO Next Target PTs 2.50-4.50 and higher^ Key Words: I'm kicking us off with my pick, which is Mereo Biopharma. Now the stock was actually popping today on an article in "The Times" that says AstraZeneca is putting in a bid for the company. As you can see there, the stock up 73% there. And AstraZeneca also getting a slight boost as well. Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year. Now Mereo is a London-based US-listed company that specializes in therapies tied to cancer and orphan diseases. Now these are the diseases designated by the FDA as deadly, but so rare that they struggle commercially, so they receive special financial benefits for developing safe and effective drugs. Mereo's stock, though, down more than 70% over the past year. Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
NASDAQ:MREOLong
by BADQOMOCAWGOWLD
Mereo Biopharma enters new $5m convertible equity Financing Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with osteogenesis imperfecta, alpha-1 antitrypsin deficiency, hypogonadotropic hypogonadism in obese men, and acute exacerbations of chronic obstructive pulmonary disease. The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom. LONDON and REDWOOD CITY, Calif., Feb 10, 2020 (GLOBE NEWSWIRE via COMTEX) -- LONDON and REDWOOD CITY, Calif., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc MREO, -4.28% (aim:MPH), "Mereo" or the "Company," a clinical stage biopharmaceutical company focused on rare diseases, today announced that it has entered into a $5 million convertible equity financing with Novartis Pharma (AG) ("Novartis") and concurrently entered into a Securities Purchase Agreement to issue up to $28 million of the Company's ordinary shares exchangeable for American Depositary Shares ("ADSs"), including a $3 million initial purchase, with Aspire Capital Fund, LLC ("Aspire Capital"), a Chicago-based institutional investor. Proceeds from these transactions are intended to be used by Mereo for general corporate purposes, including clinical trial activity and working capital. "These transactions provide us with an efficient and flexible source of capital as we continue to prepare for our upcoming Type B End-of-Phase 2 meeting with the FDA to discuss the positive data from our recently-completed Phase 2b ASTEROID study with setrusumab in adult patients with osteogenesis imperfecta ("OI"), as well as our proposed pivotal study design in pediatric OI patients. The EMA supports the initiation of the planned pivotal pediatric Phase 3 study in Europe on the basis of the previously approved pediatric investigational plan (PIP)," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "We are very pleased to have secured financing from both Novartis and Aspire, and we look forward to the continued advancement of our pipeline in 2020."
NASDAQ:MREOLong
by DEXWireNews